Journal Information
Vol. 88. Issue 4.
Pages 453-454 (October - December 2023)
Share
Share
Download PDF
More article options
Vol. 88. Issue 4.
Pages 453-454 (October - December 2023)
Letter to the Editor
Full text access
The Roussel-Uclaf hepatotoxicity causality assessment method in the context of diagnostic suspicion of drug-induced liver damage: Is it still valid?
El método de evaluación de causalidad de hepatotoxicidad de Roussel-Uclaf en el contexto de sospecha diagnóstica de daño hepático inducido por medicamentos: ¿es aún vigente?
Visits
639
C.B. Sánchez Luque
Corresponding author
carlosbsanchez938@gmail.com

Corresponding author. Calle 23 # 66-46 Oficina 808, Bogotá, Colombia. Tel. +57 13104882087.
Departamento de Medicina Interna, Sección de Gastroenterología y Hepatología, Hospital Universitario Fundación Santa Fe de Bogotá, Bogotá, Colombia
This item has received
Article information
Full Text
Bibliography
Download PDF
Statistics
Additional material (1)
Full Text
Dear Editors,

I have carefully read the interesting study “Drug-induced liver injury: Relation between the R ratio and histopathology” by O.M. Ardila-Suárez et al., published in this journal. The authors state that the diagnosis of drug-induced liver injury (DILI) is based on the ruling out of other potential causes and on the clinical capacity to establish causality between the potentially hepatotoxic substance and abnormal liver biochemical profile results and that neither the Roussel-Uclaf hepatotoxicity causality assessment method (RUCAM) nor other methods were applied because of their limitations for use in retrospective studies.1

The RUCAM emerged from a consensus meeting on adverse reactions to drugs, at which it was proposed as a method for evaluating causality. It scores different criteria for studying the probability of causality of a drug: time to onset and course of the reaction; risk factors, such as age, alcohol use, or pregnancy; the search for other causes or concomitant medications; prior knowledge of toxicity; response to rechallenge; serum levels of the medication; and validated laboratory tests. In practice, the overall scoring range would be from –5 to +13, signifying the total of arguments for or against the drug as the cause of liver injury. A score of 0 or less excludes causality probability, it is unlikely with a score of 1-2, possible with a score of 3-5, probable with a score of 6-8, and highly probable with a score over 9. Table 1 shows a model of the RUCAM, adapted from the original publication by Danan and Benichou2 (Annex. Supplementary material).

Articles analyzing the use of the RUCAM conclude that the causality assessment method adapts to prospective and retrospective studies and is a reliable tool in the context of DILI and herb-induced liver injury (HILI) for establishing the association of the cases with the suspected offending drug or herb. Thus, RUCAM should be systematically implemented and included in the clinical history of patients suspected of presenting with DILI.3

RUCAM is a validated method that is useful as a diagnostic algorithm for attaining a probable or highly probable causality score for the suspected drug. It provides a solid causality assessment of drugs suspected of involvement in DILI, which is of particular significance, given that the management of idiosyncratic DILI is considered a therapeutic challenge.4

The RUCAM appeared in 1993 and is a widely used tool worldwide for diagnosing DILI and HILI in a large number of epidemiologic studies, case reports, and case series. The RUCAM has been shown to have high sensitivity (86%) and specificity (89%), with elevated positive predictive values (93%) and negative predictive values (78%). In addition, it has shown good reproducibility results and low interobserver variability. At present, the RUCAM continues to be the main standard for causality assessment methods when drug-induced or herb-induced liver injury is suspected.5

Financial disclosure

No financial support was received in relation to this letter to the editor.

Conflict of interest

The author declares that there is no conflict of interest.

Appendix A
Supplementary data

The following is Supplementary data to this article:

References
[1]
O.M. Ardila-Suárez, L. Oriz-Benjumea, A.A. Arteta, et al.
Daño hepático inducido por medicamentos: relación entre el índice R y la histopatología.
Rev Gastroenterol Mex, 88 (2023), pp. 19-27
[2]
G. Danan, C. Benichou.
Causality assessment of adverse reactions to drugs — I. A novel method based on the conclusions of International Consensus Meetings: application to drug-induced liver injuries.
J Clin Epidemiol, 46 (1993), pp. 1323-1330
[3]
G. Danan, R. Teschke.
Roussel Uclaf causality assessment method for drug-induced liver injury: present and future.
Front Pharmacol, 29 (2019), pp. 853
[4]
Rolf Teschke.
Treatment of drug-induced liver injury.
[5]
G. Danan, R. Teschke.
Drug-induced liver injury: why is the Roussel Uclaf Causality Assessment Method (RUCAM) still used 25 years after its launch?.
Drug Saf, 41 (2018), pp. 735-743

Please cite this article as: Sánchez Luque CB. El método de evaluación de causalidad de hepatotoxicidad de Roussel-Uclaf en el contexto de sospecha diagnóstica de daño hepático inducido por medicamentos: ¿es aún vigente? Rev Gastroenterol Mex. 2023;88:453–454.

Copyright © 2023. Asociación Mexicana de Gastroenterología
Idiomas
Revista de Gastroenterología de México
Article options
Tools
Supplemental materials
es en
Política de cookies Cookies policy
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.